Teva completes sale of U.K., Ireland Actavis business to Intas’s Accord Healthcare
BY DSN STAFF
JERUSALEM and AHMEDABAD, India — The sale of Teva’s Actavis U.K. and Actavis Ireland to Intas Pharmaceuticals through its subsidiary Accord Healthcare for £603 million, Intas announced Tuesday. The transaction is part of the European Commission’s antitrust divestiture requirements surrounding Teva’s acquisition of Allergan’s generics business.
“The completion of this acquisition captures a great opportunity for growth and demonstrates Intas' commitment to greater European expansion,” Intas vice chairman and managing director Binish Chudgar said. “The joining of these two companies means we can continue our successful European operating path, which started more than a decade ago. … Through our subsidiary, Accord Healthcare, we are welcoming the Actavis team into the Intas family and will ensure a smooth integration of the two businesses.”
The deal strengthens Accord’s U.K. and Ireland footprints, expanding its manufacturing presence with the addition of Actavis’s GMP Barnstaple site and bringing its workforce in the region to more than 1,000 employees.
Teva launches generic Symmetrel
NORTH WALES, Penn. — Teva Pharmaceuticals recently launched its generic of Symmetrel (amantadine hydrochloride). The drug is indicated to treat and prevent influenza A and as a treatment for parkinsonism and drug-induced extrapyramidal reactions.
“Our customers count on Teva for a continuous supply of new generic products,” states Maureen Cavanaugh, Chief Operating Officer, North America Generics. “With the launch of Amantadine Hydrochloride Tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”
Teva’s generic is available in 100-mg dosage strength in 100-tablet bottles.
Loading Post Please Wait...